In an international collaborative effort, the International Myositis Assessment and Clinical Studies (IMACS) Group are working to standardize diagnostic and classification criteria, particularly for clinical trials. Dr. Lisa Christopher-Stine and Dr. Andrew Mammen are members of IMACS.
EID: Etanercept in Dermatomyositis: Our doctors are participating in a national clinical trial to determine whether etanercept is a safe, effective therapy for patients with dermatomyositis. Please contact us for further information.
RIM: An ongoing national study at the National Institutes of Health is evaluating rituximab for the treatment of mysoitis. The trial is directed by Dr. Fred Miller. Our Center is not a participating site, but we have referred patients from our Center for participation in this trial. Please contact us for further information.
